Navigation Links
KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K
Date:6/22/2009

the SEC on February 2, 2009, Form 12b-25 filed with the SEC on June 6, 2009, as well as certain other of the Company's SEC filings, could have a material impact on the Company's financial results; (19) the satisfaction or waiver of the other closing conditions in the previously disclosed Gestiva(TM) acquisition agreement; (20) the possibility that the auction rate securities held by the Company may not return to liquidity at their face value or at all; (21) the consent decree between the Company and the FDA and the Company's suspension of the production and shipment of substantially all of the products that the Company manufactures and the related nationwide recall affecting substantially all of the products that the Company manufactures, as well as the expected material adverse effect on the Company's revenue, assets and liquidity and capital resources, all as more fully described in the Company's Form 8-K filed with the SEC on January 26, 2009, the Company's Form 8-K filed with the SEC on February 26, 2009, the Company's Form 8-K filed with the SEC on March 3, 2009 and the Company's Form 8-K filed with the SEC on April 30, 2009; (22) the series of putative class action lawsuits alleging violations of the federal securities laws by the Company and certain individuals, all as more fully described in the Company's Form 8-K filed with the SEC on January 26, 2009, the Company's Form 8-K filed with the SEC on February 26, 2009 and the Company's Form 8-K filed with the SEC on April 30, 2009, as well as certain other of the Company's SEC filings; (23) the possibility that insurance proceeds are insufficient to cover potential losses that may arise from litigation, including with respect to product liability or securities litigation; (24) the informal inquiry initiated by the SEC and any related or additional governmental investigative or enforcement proceedings, including actions by the FDA and the U.S. Department of Justice, all as more fully described in the Company's
'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... NV (PRWEB) , ... July 31, 2015 , ... Well-known ... is now offering wedding cakes with custom designs, making life just a ... deliver beautifully designed wedding cakes for each customer who orders one. , The bakery ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... As part ... believes community involvement and support of animal welfare organizations is essential to the longevity ... third consecutive year in the National Association of Professional Pet Sitters (NAPPS) annual Presents ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the most modern ... of a visionary image that goes beyond the boundaries of fertility medicine. , ... reached extraordinary heights with dependable patient support, affordable treatments, unending hope, and high fertility ...
(Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley ... recognized in the 2015 Aster Awards national competition for a marketing communications campaign ... City and surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze ...
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
Breaking Medicine News(10 mins):Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... and reduced mobility now have access to specialized exercise ... partnership between the University of Alberta and the Spinal ... new functional electrical stimulation (FES) rehabilitation therapy machines are ... by the Faculty of Physical Education and Recreation at ...
... -- Many elderly people with dementia live and die at ... found. The findings challenge the widely held belief that ... homes, said Dr. Christopher Callahan, of the Indiana University School ... The researchers followed about 1,500 dementia patients and found ...
... , FRIDAY, May 11 (HealthDay News) -- ,Regions of the ... population of lower-income patients tend to have higher hospital readmission ... healthier population, new research finds. Factors related to supply ... than the severity of the illness or the quality of ...
... regional hospital readmission rates for heart failure are more ... than to hospital performance or patients, degree of illness, ... Quality of Care & Outcomes Research Scientific Sessions 2012., ... ― from 10 percent to 32 percent ― researchers ...
... Patrik Verstreken, associated with VIB and KU Leuven, succeeded ... defects that leads to Parkinson,s using vitamin K2. His ... done in collaboration with colleagues from Northern Illinois University ... website of the authorative journal Science ., "It ...
... Ellin Holohan HealthDay Reporter , THURSDAY, May ... in middle age could significantly reduce the ballooning cost ... of more than 20,000 people suggests. The study, ... meeting in Atlanta, found that fit middle-aged men and ...
Cached Medicine News:Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3Health News:Older People With Dementia Cared for Mostly at Home 2Health News:Availability of Beds, Poverty Drive Costly Hospital Readmissions 2Health News:Availability of Beds, Poverty Drive Costly Hospital Readmissions 3Health News:Hospital readmission rates linked to availability of care, socioeconomics 2Health News:Vitamin K2: New hope for Parkinson's patients? 2Health News:Fitness in Middle Age Lowers Medical Costs Later: Study 2Health News:Fitness in Middle Age Lowers Medical Costs Later: Study 3
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
(Date:7/30/2015)... Ohio , July 30, 2015  Cleveland Clinic ... OMTEC® 2015 keynote address last month that industry is ... in order to gain the efficiencies—and develop the transformational ... Dr. Barsoum,s comments were preceded by Doug ... entrepreneur and OMTEC moderator, who stressed that industry must ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... Jan. 28, 2011 DARA BioSciences, Inc. (NasdaqCM: ... therapeutic candidates and develops them through proof of ... to larger pharmaceutical companies, announced today that Richard ... February 3, 2011TIME: , 5:00 PM ESTLINK: ...
... Innovations, Inc. (Nasdaq: YDNT ) today announced that ... live and on-demand web cast conference call on Thursday, February ... broadcast of the call will be available through InterCall at ... also be available through the Company,s website, www.ydnt.com . ...
Cached Medicine Technology:DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 3Young Innovations, Inc. Provides 4th Quarter Conference Call Details 2
... QuickThaw Plasma Thawing Systems from Helmer use ... thaw times while ensuring the safety of your ... bag) models have dual baskets with independent controls ... ,The QuickThaw is also convenient to operate, ...
Conventional Digitally-Controlled Water Baths...
... belongs to the Flavavirus group pf viruses. ... tropics.,Symptoms of Dengue fever are the sudden ... back and limbs, lymphadenopathy,maculopapular rash and retrobulbar ... as an aid in the diagnosis of ...
... The Dengue virus belongs to the ... found commonly throughout the tropics.,Symptoms of Dengue ... headache, pain in the back and limbs, ... intended for professional use as an aid ...
Medicine Products: